Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03297697 · ClinicalTrials.gov registry record
Minimal Residual Disease in Peripheral T-cell Lymphoma
A clinical trial, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- 44
- Enrollment target
NCT03297697 is a clinical trial that has completed, run by Washington University School of Medicine. The registered enrollment target is 44 participants.
The verdict
NCT03297697 has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- 44 participants
- Enrollment target
Study Summary
As T-cell receptor sequencing by LymphoTrack is an assay with high sensitivity that can be performed in peripheral blood, the investigators wish to evaluate the ability of this assay to predict which patients are at higher risk of relapse after initial therapy for peripheral T-cell lymphomas which is being given for curative intent. Additionally, as more is known about the ability of dynamic monitoring of cfDNA in B-cell lymphomas to predict relapse, the investigators wish to explore the use of this technology in T-cell lymphomas.
Interventions
- PROCEDURE Tumor biopsy
- PROCEDURE Peripheral blood draw
- PROCEDURE Lymphotrack TCR clonality assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2017-07-31 |
| Est. Completion | 2023-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03297697
The ClinicalTrials.gov registry entry for NCT03297697 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tumor biopsy is the first listed.
NCT03297697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03297697 about?
NCT03297697 is a clinical study titled "Minimal Residual Disease in Peripheral T-cell Lymphoma". As T-cell receptor sequencing by LymphoTrack is an assay with high sensitivity that can be performed in peripheral blood, the investigators wish to evaluate the ability of this assay to predict which patients are at higher risk of relapse after initial therapy for peripheral T-cell lymphomas which i...
What is the current status of trial NCT03297697?
This trial is currently completed. The enrollment target is 44 participants. The study started on 2017-07-31. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT03297697?
The interventions under investigation include: Tumor biopsy (PROCEDURE), Peripheral blood draw (PROCEDURE), Lymphotrack TCR clonality assay (PROCEDURE).
Who is sponsoring clinical trial NCT03297697?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.